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Abstract
Icaritin, a compound from Epimedium Genus, has selective estrogen receptor (ER) modulating activities, and posses anti-
tumor activity. Here, we examined icaritin effect on cell growth of human endometrial cancer Hec1A cells and found that
icaritin potently inhibited proliferation of Hec1A cells. Icaritin-inhibited cell growth was associated with increased levels of
p21 and p27 expression and reduced cyclinD1 and cdk 4 expression. Icaritin also induced cell apoptosis accompanied by
activation of caspases as evidenced by the cleavage of endogenous substrate Poly (ADP-ribose) polymerase (PARP) and
cytochrome c release, which was abrogated by pretreatment with the pan-caspase inhibitor z-VAD-fmk. Icaritin treatment
also induced expression of pro-apoptotic protein Bax with a concomitant decrease of Bcl-2 expression. Furthermore, icaritin
induced sustained phosphorylation of extracellular signal-regulated kinase1/2 (the MAPK/ ERK1/2) in Hec1A cells and U0126,
a specific MAP kinase kinase (MEK1/2) inhibitor, blocked the ERK1/2 activation by icaritin and abolished the icaritin-induced
growth inhibition and apoptosis. Our results demonstrated that icaritin induced sustained ERK 1/2 activation and inhibited
growth of endometrial cancer Hec1A cells, and provided a rational for preclinical and clinical evaluation of icaritin for
endometrial cancer therapy.
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Introduction
Endometrial cancer is one of the most common female pelvic
malignancies and is the fourth most common type of cancer in
North American women behind lung, breast, and colon cancers,
with 42,160 new cases and 7,780 deaths estimated for 2009
[1,2,3]. About 81,500 women are affected every year in the
European Union and the incidence is increasing. Median age of
occurrence is 63 years, while .90% of women are older than 50
[4]. Although patients diagnosed with and treated for early stage-
disease of the endometrioid histology enjoy relatively good survival
rates, patients with advanced (stage III or IV, according to the
newly revised system by the International Federation of Gynecol-
ogy and Obstetrics [FIGO]) or recurrent endometrial cancer have
a poor prognosis [5]. For those women with early stage disease,
surgery with individualized use of volume directed radiotherapy is
curative [6]. For those women with advanced stage disease, there
is no real standard of care and traditionally these women are
treated with surgery, chemotherapy and radiation, in one or more
combinations. In the setting of advanced or recurrent disease,
particularly when it is not amenable to surgical resection, the
hallmark of therapy has been chemotherapy [7]. Although many
patients initially respond to chemotherapy, resistance and tumor
relapse eventually develop [5]. Thus, it is urgent to develop novel
therapeutic agents to effectively treat this deadly disease.
Icaritin (Fig. 1A) is a hydrolytic product of icariin from
Epimedium, a traditional Chinese herbal medicine. Icaritin exhibits
many pharmacological and biological activities, such as stimula-
tion of neuronal and cardiac differentiation [8,9], enhancement of
osteoblastic and suppressed osteoclastic differentiation and activity
[10], prevention of steroid-associated osteonecrosis [11], inhibition
of human prostate carcinoma PC-3 cell growth [12], induction of
human prostatic smooth muscle cells apoptosis via ERK1/2
pathway [13], and neuroprotective effects [14]. Previously, it was
reported that icaritin exhibits estrogen-like activity in estrogen
receptor-positive breast cancer MCF-7 cells at sub-micromolar
concentrations [15]. At micromolar range, however, icaritin
inhibited growth of prostate cancer PC-3 cells [12]. These results
indicated that icaritin has both agonist and antagonist activities
depending on concentrations and may function as an estrogen
receptor modulator to regulate cell growth. However, there are no
reports on activity of icaritin against endometrial cancer.
Mitogen-activated protein (MAP) kinases participate in diverse
cellular functions such as cell proliferation, cell differentiation, cell
motility, and cell death [16]. There are three major MAPK family
subgroups: extracellular signal-regulated kinase1/2 (ERK1/2), c-
Jun N-terminal of stress-activated protein kinases1/2 (JNK1/2)
and the p38 protein kinases. The signaling cascades involving JNK
and p38, activated by extracellular stress signals, are involved in
cell differentiation and apoptosis [17,18]. Previous studies have
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16781demonstrated that transient activation of ERK1/2 plays a pivotal
role in cell proliferation and that sustained ERK1/2 activation
induces cell cycle arrest and differentiation [19,20]. In the present
study, we demonstrated here that activation of ERK1/2 signaling
pathway mediates icaritin-induced apoptosis of Hec1A cells.
In the present study, we found that icaritin triggered a
mitochondrion-mediated Hec1A cells apoptosis and sustained
activation of the MAPK/ERK1/2 pathway. Our results suggested
that icaritin might be useful as an anticancer agent in endometrial
cancer therapy.
Results
Icaritin inhibits growth of endometrial cancer Hec1A cells
Previously, it was reported icaritin potently inhibited growth of
prostate cancer PC-3 cells, breast cancer cells and hepatoma
HepG2 cells [12,15,21]. We decided to examine the effect of
icaritin on growth of endometrial Hec1A cells. Cells were treated
with various concentrations of icaritin for 12 h, 24 h, and 48 h,
and cell growth was measured with the MTT assay. We found that
there was a dose-dependent and time-dependent reduction of the
growth of Hec1A cells treated with icaritin (Fig. 1B), indicating
that icaritin inhibits proliferation of Hec1A cells.
To probe the mechanism underlying icaritin-induced cell cycle
arrest, major G1 phase regulators, such as cyclin D1/cdk4 and
cyclin-dependent kinase inhibitors WAF1/p21 and KIP1/p27
were examined. As shown in Fig. 2A, icaritin treatment resulted in
a marked decrease of the expression levels of cyclin D1 and cdk4
and increase of WAF1/p21 and KIP1/p27 expression compared
to cells treated with vehicle (Fig. 2B). These data indicated that
icaritin was able to induce cell cycle arrest and to regulate cycle-
related effectors.
Icaritin induces Hec1A cells apoptosis
We next test whether icaritin also induces apoptotic cell death in
human endometrial cancer Hec1A cells. Hec1A cells were treated
with icaritin and apoptosis was assayed by two different methods.
As shown in Fig. 3A, the number of TUNEL-positive cells
increased with increased concentrations of icaritin. Nucleosome
fragmentation, an indicator of apoptosis, determined with the Cell
Death Detection ELISA further confirmed that icaritin induced
cell apoptosis at a dose- and time-dependent manner (Fig. 3B). In
Figure 1. Icaritin inhibits Hec1A cells growth. (A) The chemical structure of icaritin. (B) Effects of icaritin on the growth inhibition of Hec1A cells.
Cells were maintained in phenol red-free media with 2.5% charcoal-stripped fetal serum for 24 h, and then treated with the indicated concentration
of icaritin. Cells were harvested at different time points as the indicated and proliferation potential was assessed by MTT assay. Results of eight
independent experiments were averaged and mean 6 SEM. *, P,0.05 compared to control cells.
doi:10.1371/journal.pone.0016781.g001
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induced apoptotic cell death but not necrosis in Hec1A cells
(Fig. 3C).
Dose- and time-dependent effects of icaritin on the proteolytic
activation of caspase-3 and caspase-9 were also examined. As
shown in Fig. 4A, icaritin treatment resulted in a significant
increase in the active form of caspase-3 and caspase-9 in Hec1A
cells. The activation of caspases in icaritin treated Hec1A cells was
further confirmed by detecting the cleavage of PARP, an
endogenous substrate of activated caspase-3 and a hallmark of
apoptosis. As shown in Fig. 4B, treatment of Hec1A cells with
icaritin resulted in cleavage of PARP to an 85 kDa fragment. In
addition, we examined the subcellular localization of cytochrome c
to determine whether the mitochondria pathway is involved in
icaritin-induced apoptosis. Immunofluorescence of cytochrome c
was visualized with a confocal laser microscope. After cells were
treated with 10 mM icaritin for 24 h, the staining pattern of
cytochrome c became diffuse and blurred (Fig. 4C) in contrast to
the compact, plaque-like appearance of cytochrome c in the
control cells treated with vehicle, indicating the release of
cytochrome c from the mitochondria into the cytosol in icaritin-
treated cells.
To further determine the role of caspase activation in icaritin-
induced apoptosis, we treated Hec1A cells with the pan-caspase
inhibitor z-VAD-fmk (10 mM) before icaritin treatment. The pan-
caspase inhibitor z-VAD-fmk pretreatment abolished caspase-3
activity and reduced icaritin-induced apoptosis as measured by the
nucleosome fragmentation in Hec1A cells (Fig. 4D & E). These
results strongly suggest that activation of the caspase cascade was
essential for icaritin-induced apoptosis in Hec1A cells.
Icaritin regulates the expression of Bcl-2 family proteins
in Hec1A cells
The anti-apoptotic Bcl-2 is a potent antagonist of the
mitochondrial pathway of apoptosis initiated by a variety of extra-
and intracellular stresses. We decided to test the effects of icaritin
on the expression of anti-apoptotic protein Bcl-2 and the pro-
apoptotic proteins Bax in the Hec1A cells with the Western blot
analysis. As shown in Fig. 5, icaritin increased in the levels of Bax
expression while reduced Bcl-2 expression at a dose- and time-
dependent manner, indicating that icaritin also regulates expres-
sion levels of the Bcl-2 family proteins to facilitate apoptotic cell
death induced by icaritin.
Icaritin induces sustained ERK1/2 activation in Hec1A
cells
Cellular stresses and stimuli induce cell apoptosis via sustained
activation of the MAPK signaling pathways [22,23]. We thus
examined the activation of MAPKs ERK1/2, JNK and p38 after
icaritin treatment. As shown in Fig. 6A, the phosphorylation levels
of ERK1/2 were increased after the icaritin treatment, which last
twenty-four hours. However, no significant changes of expression
and phosphorylation levels of p38 and JNK were observed after
icaritin treatment (Fig. 6B & C). These results suggested that
sustained activation of the MAPK/ERK is involved in icaritin-
induced growth inhibition and apoptosis in HecA1 cells.
The ERK1/2 signaling pathway is involved in icaritin-
induced apoptosis in Hec1A
We than examined whether the icaritin-induced sustained
activation of the ERK1/2 signaling pathway plays a role in growth
inhibition and apoptosis. As shown in Fig. 7A & B, icaritin induced
cell apoptosis was effectively abrogated by U0126, a potent
inhibitor of MEK1/2, but the p38 inhibitor SB203580 and JNK
inhibitor SP600125 had no effect, suggesting that the activation of
ERK1/2 signaling is involved the icaritin-induced apoptosis.
Similarly, ERK1/2 inhibition by its specific inhibitor could
effectively antagonize icaritin-induced caspase-3 activity (Fig. 7C).
In addition, Western blot assay revealed that U0126 inhibited
sustained ERK1/2 activation and cleavage of PARP in icaritin
treated (Fig. 7D) while the caspase inhibitor z-VAD-fmk had no
effect on icaritin-induced activation of ERK1/2 (Fig. 7E). These
results demonstrated that the pro-apoptotic effects of icaritin in
Hec1A cells are mediated by the sustained activation of the
ERK1/2 signaling pathway.
Discussion
Here, we demonstrated that icaritin, a compound purified from
medicinal herb Epimedium, induces growth inhibition and
apoptotic cell death in human endometrial cancer Hec1A cells
at a dose and time dependent manner.
Figure 2. Effects of icaritin on cell cycle regulators in Hec1A cells. (A) Hec1A cells were treated with the indicated concentration of icaritin for
24 h. The levels of cyclin D1 and cdk4 were determined by western blot. Protein levels of b-actin were also measured as controls. (B) Hec1A cells were
treated with the indicated concentration of icaritin for 24 h. The levels of p21 and p27 were determined by western blot. Protein levels of b-actin
were also measured as controls.
doi:10.1371/journal.pone.0016781.g002
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and strictly regulated by complexes containing cdks and cyclins all
of which are critical for the normal progression of cell cycle and
inactivation of these proteins leads to cell cycle arrest [24,25,26].
The observed inhibitory effects of icaritin on the expression of
cyclin D1 and cdk4 in Hec1A cells suggested that icaritin may
arrest the cell cycle at a specific phase. Cdk activity is also
regulated by the cdk inhibitors such as WAF1/p21 and KIP1/p27
families of proteins. Here, we also showed that icaritin induced the
expression levels of the WAF1/p21 and KIP1/p27.
In many cell types, apoptosis is characterized by the generation of
DNA fragments through the action of endogenous endonucleases
[27,28]. The DNA of apoptotic cellsis cleaved into multimers of 180–
200 bp fragments, corresponding to the oligonucleosomal size.
Therefore, the DNA of apoptotic cells typically migrates as a ladder
of 180–200 bp multimers on an agarose gel. The Terminal
deoxynucleotidy Transferase Biotin-dUTP Nick End Labeling
(TUNEL) method identifies apoptotic cells in situ by using terminal
deoxynucleotidyl transferase (TdT) to transfer biotin-dUTP to these
strand breaks of cleaved DNA [29]. The ELISA assay determination
of the cytoplasmic histone-associated DNA fragments (mono- and
oligonucleosomes) after induced cell death [30]. Annexin V is used to
quantitatively determine the percentage of cells within a population
thatareactivelyundergoingapoptosis.Itreliesonthepropertyofcells
to lose membrane asymmetry in the early phases of apoptosis. In
apoptotic cells, the membrane phospholipid phosphatidylserine (PS)
is translocated from the inner leaflet of the plasma membrane to the
outer leaflet, thereby exposing PS to the external environment.
Annexin V is a calcium-dependent phospholipid-binding protein that
has a high affinity for PS, and is useful for identifying apoptotic cells
with exposed PS. Propidium Iodide (PI) is a standard flow cytometric
viability probe and is used to distinguish viable from nonviable cells.
Viable cells with intact membranes exclude PI, whereas the
membranes of dead and damaged cells are permeable to PI. Cells
that are considered viable are annexin V and PI negative; cells that
are in early apoptosis are annexin V positive and PI negative; cells
that areinlateapoptosisarebothannexinVandPIpositive;andcells
that are in necrotic are annexin V negative and PI negative [31]. The
annexin V/PI staining method distinguishes apoptosis cells and
necrosis cells. In the present study, Hec1A cells were treated with
icaritin and apoptosis was assayed by using TUNEL and ELISA
assay. Furthermore, an annexin V-binding assay showed that icaritin
treatment induced apoptosis but not necrosis in Hec1A cells.
Mitochondria play a pivotal role in the signal transduction of
apoptosis [32]. The observation of icaritin-mediated activation of
caspase-9, caspase-3, subsequent cleavage of PARP and release of
cytochrome c, as well as the result that the pan-caspase inhibitor z-
VED-FMK almost completely blocked icaritin-induced apoptosis
in Hec1A cells, suggesting that mitochondrial-mediated caspase
cascade pathway plays a very important role in icaritin-induced
apoptosis [33].
Bcl-2 family of proteins, including Bcl-2 and Bcl-2-related
family members such as Bcl-xL, Bad and Bax, plays an important
role in the regulation of apoptosis. They can activate or inhibit the
release of downstream factors such as cytochrome c which leads to
the activation of caspase-3 and PARP in the execution of apoptosis
[34]. Bax exerts pro-apoptotic activity by translocation from the
cytosol to the mitochondria, where it induces cytochrome c
release, while Bcl-2 exerts its anti-apoptotic activity, at least in
part, by inhibiting the translocation of Bax to the mitochondria
[35]. Obviously, the ratio of pro- and anti-apoptotic protein
expression, such as Bax/Bcl-2, is critical for the induction of
apoptosis, and it decides the susceptibility of cells to undergo
apoptosis [36]. In the present study, we showed that treatment of
the Hec1A cells with icaritin resulted in significant decrease in the
Bcl-2 protein and increase in the Bax protein, thus shifting the
Bax/Bcl-2 ratio in favor of apoptosis. Taken together, our results
indicated that icaritin regulates expression levels of the Bcl-2
family, induces cytochrome c release and trigs caspase-dependent
cell apoptotic death.
The family of MAPKs, ERK, SAPK/JNK1/2 and p38, plays
central roles in cell proliferation, differentiation, survival, and
apoptosis, including extracellular-regulated kinase1/2 [37,38]. In
general, transient ERK1/2 activation occurs rapidly and decline
with30–45 min, which is considered to lead to cell proliferation and
survival [39], but persistent or sustained ERK1/2 activation that
last more than 12 h is involved in cell differentiation and death
[40,41,42,43]. The dual activities of ERK1/2 in both cell
proliferation and cell death may be explained by several recent
findings that demonstrate that phosphorylated ERKs may produce
different outcomes, depending on the duration of ERK accumu-
lation in the nucleus [44,45]. Recently, it has been reported that
sustained ERK activation was involved in calcium-induced
apoptosis of lens epithelial cells [46]. Several studies have shown
that icaritininduces activation ofERKand p38 kinaseinembryonic
stem cells and neuronal cells [8,14]. Chen et al. reported that
icaritin induces growth inhibition and apoptosis of human prostate
cancer PC-3 cells through the ERK1/2 signaling pathway [13].
Here we also found that icaritin induced sustained activation of the
ERK1/2, but not JNK and p38 in Hec1A cells. U0126, a specific
inhibitor of MEK (the MAPK/ERK kinase), effectively blocked
icaritin-induced ERK1/2 activation and attenuated icaritin-
induced apoptosis, suggesting that the sustained activation of the
ERK1/2 signaling pathway is one of the mechanisms.
In conclusion, we found that icaritin inhibited cell growth and
induced cell apoptosis in Hec1A cells. We also studied the
underlying mechanisms involved in icaritin-induced apoptosis.
Our results indicated that icaritin-induced cell growth inhibition
involves the reductions of cyclin D1 and cdk4 protein expression
and inductions of p21 and p27 protein expression. Our results also
demonstrated that icaritin-induced apoptosis involves the activa-
tion of caspase-3 and caspase-9 and release of cytochrome c. We
found that sustained ERK1/2 activation was required for icaritin-
induced apoptosis. Our results provided a rational that icaritin
could be developed as a potential anticancer agent against human
endometrial cancer.
Materials and Methods
Materials and Reagents
Icaritin with a purity of up to 99.5% was from Dr. Kun Meng
(shenogen Pharma Co Beijing, China). A stock solution (10 mM)
was prepared by dissolving icaritin in DMSO (sigma, St Louis,
MO, USA) and stored at 220uC. MTT, DAPI, U0126,
Figure 3. Icaritin induced Hec1A cells apoptosis. (A) Visualization of apoptotic cells by the TUNEL assay on Hec1A cells. (B) DNA fragmentation
was evaluated using a Cell Death Detection ELISA kit. The data are expressed as mean 6 SEM of three separate experiments. *, P,0.05 compared to
control cells. (C) The apoptotic status was determined by Annexin V/PI staining method. Percentages of negative (viable) cells, annexin V-positive
(early apoptotic) cells, PI-positive (necrotic) cells, or annexin V and PI double-positive (late apoptotic) cells were shown (mean of three independent
experiments) by a flow cytometry analysis.
doi:10.1371/journal.pone.0016781.g003
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e16781Figure 4. Induction of caspases activities by icaritin. (A) Hec1A cells were treated with the indicated icaritin concentration or the indicated
time points, total cellular extracts were prepared and subjected to Western blot assay to measure levels of cleaved-caspase-3 and cleaved-caspase-9.
Protein levels of b-actin were also measured as controls. (B) Hec1A cells were treated with the indicated icaritin concentration or the indicated time
points, total cellular extracts were prepared and subjected to Western blot assay using antibodies against PARP. Protein levels of b-actin were also
measured as controls. (C) Hec1A cells were fixed and labeled for cytochrome c (red) and DNA (blue). (D) Hec1A cells were pretreated with 10 mMo fz -
VAD-fmk for 1 h, followed with 10 mM icaritin for 24 h, and DNA fragmentation and caspase-3 activity were determined. The data are expressed as
mean 6 SEM of three separate experiments. *, P,0.05 compared to control cells. (E) Hec1A cells were pretreated with 10 mM of z-VAD-fmk for 1 h,
followed with 10 mM icaritin for 24 h. Protein extracts were prepared and subjected to Western blot assay using antibody against PARP. Protein levels
of b-actin were also measured as controls.
doi:10.1371/journal.pone.0016781.g004
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were purchased from Calbiochem (San Diego, CA). Antibody for
cleaved caspase-3 was purchased from Cell Signaling (Beverly,
MA). Antibodies against ERK1/2, phospho-ERK1/2, p38,
phospho-p38, JNK, phospho-JNK, p21, p27, cytochrome c, Bcl-
2, Bax, cleaved caspase-9, cyclin D1, cdk4, PARP and b-actin
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
FITC Annexin V Apoptosis Detection Kit I was purchased from
Becton Dickinson (PharMingen).
Cells culture and cell proliferation essay
The human endometrial cancer cell line Hec1A was obtained
from Dr. Li-Hui Wei (Peking University People’s Hospital, Beijing)
and cultured in Dulbecco’s modified Eagle’s medium (Gibco-BRL,
USA) medium with 10% fetal calf serum (Hyclone, UT), 5 ug/ml
insulin, and maintained at 37uC in a humidified atmosphere of 5%
CO2. Media will be changed in phenol red-free media with 2.5%
charcoal-stripped fetal calf serum for 24 h before experiments
needed.
Cells were seeded in a 96-well dish to a final concentration of
1610
4 cells/well and incubated in DMEM medium containing
10% FCS for 24 h. Then Cells were cultured in phenol-red-free
DMEM (Gibcol-BRL, USA) with 2.5% charcoal-stripped fetal
calf serum (Biochrom AG, Germany) followed by treatment with
varying concentrations of icaritin for 12 h, 24 h, and 48 h.
Medium was removed and fresh medium was added to each well
along with 20 ml of MTT solution (5 mg/ml). After 4 h
incubation, 150 ml of DMSO were added to each well. The
Figure 5. Effects of icaritin on the expression of Bcl-2 family. (A) Hec1A cells were treated with the indicated concentration of icaritin, total
cellular extracts were prepared and subjected to Western blot assay to measure levels of Bcl-2 and Bax. Protein levels of b-actin were also measured
as controls. (B) Hec1A cells were treated with the indicated icaritin time points of icaritin, total cellular extracts were prepared and subjected to
Western blot assay to measure levels of Bcl-2 and Bax. Protein levels of b-actin were also measured as controls.
doi:10.1371/journal.pone.0016781.g005
Figure 6. Effects of icaritin on MAPK pathways. Hec1A cells were treated with the indicated icaritin concentration or the indicated interval, total
cellular extracts were prepared and subjected to Western blot assay to measure levels of phosphorylated forms of ERK1/2 (A), JNK (B) and p38 (C).
Membranes were reprobed with antibodies against total ERK1/2, JNK and p38 for normalization.
doi:10.1371/journal.pone.0016781.g006
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reader (Bioteck Powerwave
TM, USA). Eight reduplicate wells
were used for each treatment, and experiments were repeated
three times.
Western Blot Analysis
Western blot was performed as described previously [47,48].
Cells were treated with the indicated concentration of icaritin for
the indicated time in phenol-red-free DMEM (Gibcol-BRL,
USA) with 2.5% charcoal-stripped fetal calf serum (Biochrom
AG, Germany). The cells were collected in ice-cold PBS, and the
cell extracts were prepared in RIPA buffer with proteinase
inhibitor cocktail from Sigma (St.Louis, MO). The protein
concentrations of the cell lysates were determined and boiled
with gel-loading buffer for 10 min at 100uC. Samples containing
30 mg of total protein were electrophoresed on 10% SDS-
polyacrylamide gels and transferred to PVDF membrane
(Millipore, Temecula, CA). Following transfer, the membrane
were blocked in TBST (TBS containing 0.1% Tween 20)
containing 5% skimmed milk for 2 h, followed by incubation
overnight at 4uC with appropriate primary antibodies. After
washing three times in TBST, the membranes were incubated for
1 h at 37uC with 1:2000 horseradish peroxidase-conjugated
appropriate secondary antibodies. Finally, the membranes were
visualized using the enhanced chemiluminescence detection
system (Amersham, Piscataway, NJ).
TUNEL Assay
Potential DNA fragmentation was examined with fluorescence
staining by the TUNEL (Terminal Transferase dUTP Nick End
Labeling) apoptosis detection kit (Beyotime Biotech, China)
following the manufacturer’s instruction. Briefly, cells cultured
on sterile glass coverlips were fixed with 4% paraformaldehyde in
PBS for 10 min, and then permeabilized with 0.4% Triton X-100
for 10 min at room temperature. Cells were incubated with a
reaction mix containing biotin-dUTP and the terminal deoxynu-
cleotidyl transferase (TdT) for 60 min and then with the avidin-
FITC solution for 30 min in the dark. DAPI was subsequently
added for nuclear staining. Microscopic analysis was performed
using a confocal laser-scanning microscope (Zeiss LSM 710
META, Germany).
Apoptosis Detection by Cell Death Enzyme-Linked
Immunoabsorbent Assay Method
For ELISA, the cells seeded in 96-well plates (1610
4 cells/well)
were treated with icaritin, then apoptotic cells were evaluated by
using Cell Death Detection ELISA kit (Roche Diagnostics,
Mannhein, Germany) according to the manufacturer’s instruction.
Photometric enzyme immunoassay was used to quantitatively
determine the formation of cytoplasmic histone-associated DNA
fragments in the form of mononucleosomes after apoptosis of the
cells. Absorbance at 405 nm was measured as the indicator of
apoptotic cells. The reference wavelength was 490 nm. The
enrichment factor (total amount of apoptosis) was calculated by
dividing the absorbance of the sample (A405 nm) by the
absorbance of the controls without treatment (A490 nm).
Annexin V/PI assays for apoptosis
For Annexin V/PI assays, cells were stained with Annexin V-
FITC and PI, and evaluated for apoptosis by flow cytometry
according to the manufacturer’s protocol (BD PharMingen, San
Diego, CA, USA). Briefly, 1610
6 cells were washed twice with
PBS, and stained with 5 ml of Annexin V-FITC and 10 mlo fP I
(5 mg/ml) in 1 ml binding buffer for 15 min at room temperature
in the dark. The apoptotic cells were determined using a Becton-
Dickinson FACScan cytoflurometer (Mansfield, MA, USA).
Figure 7. Icaritin induced Hec1A cells apoptosis was mediated through ERK1/2 activation. (A) Hec1A cells were treated with icaritin in the
presence or absence of 10 mM U0126, 10 mM SP600125, or 40 mM SB203580 for 24 h, Cell growth was determined by MTT. The bars represent the
mean 6 SEM of three separate experiments. *, P,0.05 compared for the icaritin-treated group. (B) Hec1A cells were treated with icaritin in the
presence or absence of 10 mM U0126, 10 mM SP600125, or 40 mM SB203580 for 24 h, and DNA fragmentation was determined. The data are
expressed as mean 6 SEM of three separate experiments. *, P,0.05 compared to icaritin-treated cells. (C) Hec1A cells were treated with icaritin in the
presence or absence of 10 mM U0126, 10 mM SP600125, or 40 mM SB203580 for 24 h, and caspase-3 activity was determined by caspase-Glo assay.
The data are expressed as mean 6 SEM of three separate experiments. *, P,0.05 compared to icaritin-treated cells. (D) Hec1A cells were pretreated or
not pretreated with 10 mM U0126 then added with DMSO (vehicle) or 10 mM icaritin for 12 h, 24 h respectively. Protein extracts were prepared and
subjected to Western blot assay to measure levels of phosphorylated ERK1/2. Protein levels of ERK1/2 were also measured as controls. (E) Hec1A cells
were pretreated or not pretreated with 10 mM U0126 then added with DMSO (vehicle) or 10 mM icaritin for 12 h, 24 h respectively. Protein extracts
were prepared and the cleavage of PARP was analyzed with Western bolt. Protein levels of b-actin were also measured as controls. (F) Hec1A Cells
were pretreated with or without z-VAD-fmk (10 mM) were further incubated with 10 mM icaritin for 24 h. Protein extracts were prepared and
subjected to Western blot assay to measure levels of phosphorylated ERK1/2. Protein levels of ERK1/2 were also measured as controls.
doi:10.1371/journal.pone.0016781.g007
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Immunofluorescence staining was used to analyze the Subcel-
lular distribution of cytochrome c in Hec1A cells induced by
Icaritin. Cells cultured on sterile glass coverlips were fixed with 4%
paraformaldehyde in PBS for 10 min. After permeabilized with
0.4% Triton X-100 for 10 min at room temperature, cells were
blocked in 4% BSA-supplemented PBS for 1 h and incubated
overnight at 4uC with anti-cytochrome c antibody. After washing
three times in PBS, cells were labeled with TRITC-conjugated
secondary antibody. DAPI was subsequently added for nuclear
staining. Microscopic analysis was performed using a confocal
laser-scanning microscope (Zeiss LSM 710 META, Germany).
Measurement of caspase-3 activity
Cells were treated with icaritin in the absence and presence of
different kinase inhibitors, and the caspase-3 activity in the cleared
lysates were measured by using Caspase-3 Activity Assay Kit
(Beyotime Biotech, China) according to the manufacturer’s
instruction. Luminescence was quantified using an ELISA reader.
Blank values were subtracted, and increases in caspase-3 activities
were expressed as fold increase and calculated based on activities
measured from untreated cells. Each sample was measured in
triplicates.
Statistical analysis
Statistical analysis was performed with the paired-samples t-test,
or ANOVA followed by the Student-Newman-Keuls testing to
determine differences in means. A level of P,0.05 was considered
statistically significant. All statistical tests were three-sided.
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